REGN - Regeneron Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $823.11 DETAILS

Stock News

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Jul 09, 2026 05:56 AM • zacks.com

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Jul 07, 2026 09:11 AM • zacks.com

Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”

On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.

Jul 07, 2026 08:30 AM • 247wallst.com

Here's Why Regeneron (REGN) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Jul 07, 2026 06:41 AM • zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Jul 07, 2026 05:56 AM • zacks.com

Why Regeneron (REGN) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Jul 02, 2026 06:51 AM • zacks.com

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%

It might pull it off, provided several things fall right in place.

Jul 01, 2026 11:45 AM • fool.com

FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports

The U.S. Food and ‌Drug Administration has selected Eli Lilly and Regeneron , ⁠among seven companies, for a pilot program to accelerate reviews of ‌new ⁠domestic pharmaceutical manufacturing facilities, CNBC reported on ⁠Monday citing an FDA ⁠spokesperson.

Jun 29, 2026 11:03 AM • reuters.com

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA's PreCheck pilot program. The FDA PreCheck program is designed to accelerate regulatory review of new pharmaceutical manufacturing facilities.

Jun 29, 2026 10:50 AM • cnbc.com

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

Parabilis saw its shares rise by more than SpaceX's shares did after its IPO. That doesn't mean it's guaranteed to succeed.

Jun 27, 2026 04:00 PM • fool.com

From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - Investorideas.com, a leading investment platform for retail investors

Jun 26, 2026 03:00 AM • feeds.newsfilecorp.com

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursday, July 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Jun 25, 2026 12:05 PM • globenewswire.com

Is AbbVie a Buy After Its Purchase of Apogee?

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

Jun 25, 2026 05:53 AM • fool.com

Regeneron's Applications for gMG Drug Accepted by FDA and EMA

Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially unique dosing schedule.

Jun 23, 2026 11:26 AM • zacks.com

2 Underrated Weight Loss Stocks to Buy and Hold

They look well-positioned to grab a slice of the fast-growing anti-obesity market.

Jun 22, 2026 10:45 PM • fool.com

Breakfast News: AbbVie's $11 Billion Pounce

AbbVie reportedly set to take over Apogee, Satya Nadella wants to upturn AI, and more

Jun 22, 2026 03:30 AM • fool.com

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing

Jun 22, 2026 03:00 AM • globenewswire.com

This Stock Is Up 58% This Year. Is It too Late to Buy?

There could be additional catalysts for this drugmaker over the next year.

Jun 16, 2026 10:30 PM • fool.com

Here's Why Regeneron (REGN) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Jun 12, 2026 06:41 AM • zacks.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Jun 11, 2026 06:00 AM • prnewswire.com (Hide legal announcements)